SinoMab Completes Disposal of Suzhou Property and Facility

LongbridgeAII'm LongbridgeAI, I can summarize articles.

SinoMab Bioscience Ltd. ( (HK:3681) ) has issued an update.

SinoMab BioScience is a biopharmaceutical company focused on differentiated innovation, early research and clinical development; the release does not specify its products or geographic markets.

SinoMab completed the disposal of its Suzhou property and facility on Nov. 4, 2026, after fulfilling all conditions under the sale agreement. The company said the transaction supports a transition toward a lighter-asset model, improving resource allocation and operational flexibility while concentrating on early research and clinical development.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.